Stroke is the second most common cause of death 2 and major cause of disability worldwide, 2 with survivors often depending on lifelong care. Carotid stenosis is the second most common predecessor of ischemic stroke, 3 and carotid endarterectomy (CEA; and to a lesser extent carotid artery stenting) are accepted as secondary, but also primary preventive therapy. 2, 4, 5 With new imaging techniques, vulnerable plaques at risk of rupture can be identified with increasing accuracy, 6 but in the majority of cases, the perioperative surgical risk of ≈3% still outweighs the risk of plaque rupture in asymptomatic carotid stenosis carriers.
A therosclerosis is characterized by the development of vascular lesions commonly referred to as plaques or atheromas and has various stages, of which most remain clinically silent. 1 Disruption of a vulnerable atherosclerotic plaque classically marks the onset of clinical symptoms. 1 Identification and stabilization of a vulnerable plaque would be of great value in patients at risk of lesion rupture. February 17, 2017
MicroRNAs (miRNAs) are 20-to 22-nucleotide long endogenous RNA molecules and known as post-transcriptional negative regulators of gene expression. 9 Up to 60% of all mammalian genes are reported to be under the influence of miRNAs, many of which are highly conserved throughout species. 10 Together, these facts imply a disease-modifying potential for miRNA mimics (premiRs) and inhibitors (antagomiRs), and indeed antagomiRs have proven their therapeutic potential in clinical trials. 11 Unlike mRNA, which is prone to degradation in the circulation, miRNAs associate with diverse types of stabilizing carriers such as microparticles and exosomes, 12 allowing them to be detected as disease biomarkers. 13 We used a human array of lesion site plasma, obtained during CEA and laser capture microdissection (LCM) of plaque tissue, to identify miR-210 repression in high-grade carotid stenosis patients with symptoms of atherosclerotic plaque rupture versus asymptomatic CEA subjects. Using 2 distinct murine plaque models, we were able to decipher an antiapoptotic role for miR-210 in smooth muscle cell (SMC)-enriched fibrous caps, altering the pathological consequence in vivo. Exposing vascular cells to various disease-relevant stimuli in vitro allowed us to pinpoint APC (adenomatous polyposis coli) as a miR-210 target essential in carotid plaque vulnerability.
Methods

CEA Plasma Array
Patients undergoing surgery for symptomatic or asymptomatic highgrade (>50% NASCET [North American Symptomatic Carotid Endarterectomy Trial]) carotid stenosis at the Department for Vascular Surgery, Karolinska University Hospital, were consecutively enrolled in the BiKE (Biobank of Karolinska Endarterectomies) and clinical data recorded on admission. The BiKE study cohort demographics and details of sample processing including control (normal artery) samples have been previously described.
14 Briefly, symptoms of plaque instability were defined as transient ischemic attack, minor stroke, or amaurosis fugax. Patients without qualifying symptoms within 6 months before surgery were categorized as asymptomatic and indication for CEA based on results from the ACST (Asymptomatic Carotid Surgery Trial). 7 Patients with known atrial fibrillation were excluded. For this study, CEA tissue and blood samples from n=7 symptomatic and n=5 asymptomatic subjects were collected during surgery. We validated our findings in local plasma samples in a separate BiKE validation cohort of 7 symptomatic versus 7 asymptomatic patients. During clamping of the carotid artery for 5 minutes before opening of the vessel, blood from the lesion site was sampled in EDTA-containing tubes (BD Pharmingen, Franklin Lakes, NJ, USA). The resultant plasma samples were stored at −80°C before further processing. Hemolytic plasma samples were excluded from miRNA analysis (Methods in the Online Data Supplement). All studies were approved by the Ethical Committee of Northern Stockholm; patient informed consent was obtained according to the Declaration of Helsinki.
Ruptured Versus Stable Carotid Plaques for Histology and miR-210 In Situ Hybridization
For histology and miR-210 in situ hybridization (ISH), we used CEA material from the Munich Vascular Biobank (Department of Vascular Surgery, Technical University Munich, Germany). These plaques were morphologically graded according to the Atherosclerosis Council of the American Heart Association classification, 15 with or without a 
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vulnerable fibrous cap according to Redgrave et al. 16 Tissue preparation is described in the Methods in the Online Data Supplement.
LCM of Vulnerable Versus Stable Carotid Plaques
Human atherosclerotic carotid artery lesions were obtained from patients undergoing CEA for asymptomatic (n=10) or symptomatic (n=10) carotid stenosis. A detailed description of the LCM is provided in the Methods in the Online Data Supplement.
Selection of miR-210 Targets for Functional Analysis
Information on experimentally validated 17 or predicted 18 miR-210 targets was extracted from the literature to obtain a workable gene list. Next, expression of miR-210 target genes in carotid plaques was examined in previously published BiKE data sets (Gene Expression Omnibus accession number GSE21545), 14 to identify significantly deregulated genes comparing plaques versus control arteries and plaque from symptomatic versus asymptomatic subjects. Finally, miR-210 target gene expression in plaques was validated by quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) analysis (Methods in the Online Data Supplement).
APC Luciferase Reporter Assay
Luciferase reporter assay was performed as described previously. 19 In brief, HEK293 cells (Public Health England Culture Collections, Salisbury, United Kingdom) or human carotid artery SMC (HCtASMCs; Cell Applications, San Diego, CA) were seeded on 24-well plates (1×10 5 cells/well). At 50% to 60% confluence, cells were transfected with luciferase reporter plasmid pLS, pLS-APC-3′ untranslated region (3′UTR), or its mutant (100 ng/well; Active Motif, Switchgear Genomics and Thermo Fisher Scientific, Waltham, MA), together with control or premiR-210 (10 nmol/L final concentration) using FuGENE HD Transfection Reagent (Thermo Fisher Scientific) according to the manufacturer's protocol. After a 24-hour transfection period, luciferase activity was quantified using the LightSwitch Luciferase Assay Kit (Thermo Fisher Scientific) according to the manufacturer's instructions.
Animal Studies
Rat Carotid Artery Balloon Injury Model
Injury of the common carotid artery in rats was performed as previously described 20 in accordance with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996). For experimental and sample-processing details, please refer to the Methods in the Online Data Supplement.
Mouse Atherosclerosis/Carotid Plaque Rupture Model
All experiments were performed in male, 12-week-old apolipoprotein E knockout (Apoe −/− C57Bl/6J) mice (Taconic Biosciences, Hudson, NY), weighing 25 to 30 g, and in accordance with the guidelines on laboratory animal use issued by the Swedish Board of Agriculture. To assess effect of miR-210 modulation on atherosclerosis per se, mice were injected with miR-210 modulators once per week for 4 weeks and euthanized at 16 weeks of age. To induce carotid plaque rupture, we used a modified version of the carotid ligation/cast approach first described by Sasaki et al 21 (n=48) . For experimental and sample-processing details, please refer to the Methods in the Online Data Supplement and the Online Movie file.
In Vivo miR-210 Modulation
For inhibition of miR-210, we used 10 mg/kg locked nucleic acidcarried anti-miR-210 (Exiqon, Vedbaek, Denmark) diluted in PBS. Mice receiving inhibitors were injected intraperitoneally once per week (n=6, atherosclerosis) or 1 day before cast placement (n=18, plaque rupture). Control animals (n=14, plaque rupture) received 10 mg/kg locked nucleic acid-carried scrambled miRNAs following the manufacturer's instructions. For tracking purposes, we used FAM (carboxyfluorescein)-labeled locked nucleic acid oligonucleotides in 2 of these animals. For miR-210 overexpression, we used 2 mg/kg miR-210 mimic (Ambion; Thermo Fisher Scientific) using Jet-PEI (Polyplus-Transfection, Illkirch-Graffenstaden, France) as vector. Mimics were injected intraperitoneally once per week (n=6, atherosclerosis) or on 5 consecutive days starting 1 day before cast placement (n=26, plaque rupture). Controls received Jet-PEI carried mismatch (scrambled) control miRNAs (n=6, atherosclerosis; n=11, plaque rupture) to a final concentration of 0.5 mg/kg, according to the manufacturer's instructions.
Tissue Histology and Immunohistochemistry
Tissue preparation and histology methods are described in the Methods in the Online Data Supplement. For immunohistochemistry, we used standard biotin-avidin-immunoperoxidase methods with the following Abcam (Cambridge, United Kingdom) primary antibodies: α-smooth muscle actin, von Willebrand factor, APC, and galectin (Macrophage-2 glycoprotein). CD4 and CD19 antibodies were obtained from BD Pharmingen and prediluted CD3 antibody from Biocare Medical (Concord, CA).
For immunofluorescent staining, we used standard immunofluorescent techniques modified for mouse-on-mouse staining (M.O.M. Basic Kit; Vector Laboratories, Peterborough, United Kingdom) with an antibody against fibrin that does not cross-react with fibrinogen. 22 As secondary antibody, we used Alexa Fluor 488 goat anti-mouse secondary antibody (Thermo Fisher Scientific) at a 1:200 dilution. We counterstained with Hoechst (bisBenzimide H 33258; Sigma Aldrich, St. Louis, MO). All antibodies and dilutions are listed in Online Table V.
In Situ Hybridization
For ISH, we used an Exiqon miRCURY locked nucleic acid DIG (digoxigenin)-labeled probe (5′-3′ sequence: /5DigN/TCAGCCGCTGT CACACGCACAG/3Dig_N/) with the accompanying kit and protocol (Exiqon). In brief, tissue sections were either deparaffinized (formalin-fixed paraffin embedded) or thawed (frozen) and rehydrated. Nucleases were inactivated with proteinase K followed by a 2-hour hybridization at hybridization temperature (62°C for miR-210). Slides were washed in saline-sodium citrate buffers with subsequent DIG detection methods. Nuclear counterstaining was performed with Nuclear Fast Red (Sigma Aldrich).
In Vitro Experiments
Cell Shear Stress Exposure Model
Experimental details for studies in primary human carotid artery smooth muscle cells (SMCs) and endothelial cells (HCtASMCs and human carotid artery endothelial cells; Cell Applications), using the Streamer apparatus (Flexcell International Corporation, Burlington, VT) with adjustable flow and shear stress conditions are described in the Methods in the Online Data Supplement.
Cell Stimulation and miRNA Modulation
HCtASMCs were transfected with miRNA modulators or scrambled control (Ambion; Thermo Fisher Scientific) using lipofectamine RNAiMAX Transfection Agent (Invitrogen; Thermo Fisher Scientific). To assess cell proliferation, miR-210 modulator or control transfection was followed by Vybrant MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay (Thermo Fisher Scientific) according to the manufacturer's protocol. For fluorescent microscopy and fluorescence-activated cell sorter analysis, Cy3-labeled scrambled control oligonucleotides were used. Transfection time was 24 hours. A line of nonstarved cells served as normalization control. Experiments were repeated 3×. Further details are described in the Methods in the Online Data Supplement.
p53 Knockdown
HCtASMCs (Lonza, Walkersville, MD; passages 4-5) were propagated in SmGM-2 (smooth muscle growth medium-2) growth media (Lonza) containing 5% fetal bovine serum. Cells were serum starved in basal media (SmBM) for 48 hours or placed in the Streamer for 1 hour. p53 inhibition studies were completed by adding 10 μmol/L pifithrin-α (Merck Millipore, Darmstadt, Germany), diluted in dimethyl sulfoxide, to the cell culture media. Control cells received dimethyl sulfoxide only.
Terminal Deoxynucleotidyl Transferase-Mediated dUTP (deoxyuridine triphosphate) Nick-End Labeling Assay
Terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) assay was performed using the Click-iT TUNEL Alexa February 17, 2017
Fluor Imaging Kit (Invitrogen) in accordance with the manufacturer's protocol (Methods in the Online Data Supplement).
Fluorescent Immunocytochemical Staining
Fluorescent immunocytochemical staining was performed on HCtASMCs grown on cover slips. Cells at 70% to 80% confluency were transfected with either APC siRNA or scrambled control oligonucleotides (30 μmol/L; Thermo Fisher Scientific) for 48 hours with or without etoposide (Sigma Aldrich) treatment at a final concentration of 10 μmol/L for 24 hours. After fixation and permeabilization, the cells were incubated with caspase-3 antibody (Merck Millipore; dilution 1:50) or APC antibody (Abcam; dilution 1:50) following standard immunocytochemistry techniques described in the Methods in the Online Data Supplement.
Wnt (Wingless-related integration site) Signaling Activity Assay
Wnt-β-catenin signaling activity analyses were performed using a T-cell factor/lymphoid enhancer factor (TCF/LEF) luciferase reporter assay (Qiagen, Hilden, Germany) according to the manufacturer's protocol. Briefly, HEK293 cells (Public Health England Culture Collections) or HCtASMCs (Cell Applications) were seeded on 96-well plates (2×10 4 cells/well) containing anti-miR-210, miR-210 mimic or scrambled oligonucleotides (all from Ambion; Thermo Fisher Scientific) and a TCF/ LEF responsive firefly luciferase reporter construct (Qiagen) or negative control reporter, using DharmaFECT Duo transfection reagent (GE Healthcare, Little Chalfont, United Kingdom). After 24 hours, transfection medium was replaced by growth medium enriched with 10 μmol/L lithium chloride, to stimulate endogenous Wnt signaling activity. To confirm successful transfection, cells were cotransfected with a Renilla luciferase construct. Forty-eight hours after transfection, we analyzed firefly and Renilla luciferase activity using a luciferase reporter assay (Promega, Madison, WI) on a GloMax-96 Microplate Luminometer (Promega).
RNA Isolation and qPCR Analysis
Sample preparation and standard qPCR analysis is available in Methods in the Online Data Supplement. As internal normalization controls, spike-in C. elegans miR-39, small nucleolar RNA, C/D box 48 (RNU48, human), SNORD87 small nucleolar RNA (rat), and small nucleolar RNA, MBII-202 (sno202, mouse) were used. Housekeeping mRNA genes used were RPLP0 (ribosomal protein lateral stalk subunit P0; human), Hprt1 (hypoxanthine phosphoribosyltransferase [1] ; rat), and Hprt (mouse). Mature miRNA sequences, control sequences, and gene NCBI Reference Sequences are listed in Online Tables VI, VII, and VIII, respectively.
Western Blot Analysis
Protein isolation is available in Methods in the Online Data Supplement. Western blot was performed with an anti-human APC antibody (ab15270, dilution 1:500, Abcam). APC Western blotting showed 2 bands (Online Figure VIIB) , 1 for the full-length protein (300 kDa) and 1 for a truncated splice form (120 kDa). This truncated APC has been shown in cancer cells and is associated with proliferation. 23 β-actin (A1978, dilution 1:5000; Sigma Aldrich) served as loading control. Densitometric quantification was performed using ImageJ64 software. Western blotting was performed with n=3 for both treatment groups.
Statistical Methods
SPSS Statistics version 22 (IBM) was used to analyze patient data.
To compare 2 groups, a Student t test was used. Paired data were analyzed by paired-samples t test. Differences between ≥2 groups versus a control group were analyzed with 1-way ANOVA plus Bonferroni correction for multiple comparisons. Percentages were analyzed with χ 2 testing. Nonparametric data were analyzed by Mann-Whitney U test. Statistical analysis for experiment data was performed using Graphpad Prism software version 6.0b. Differences in RNA expression were calculated as fold change versus control using the mean ΔCt (defined as Ct 
Results
miR-210 Is Downregulated in Local Plasma and Tissue of the Fibrous Cap in Patients With Symptomatic Carotid Stenosis
Patients undergoing CEA for either symptomatic or asymptomatic carotid artery disease were selected based on symptoms (Online Table I ). Microarray analysis of plasma locally sampled close to the carotid plaque lesion showed that 2 out of 742 miRNAs (miR-210 and miR-29c) were downregulated in 7 symptomatic versus 5 asymptomatic patients. Six miRNAs (miR-30c, miR-15b, miR-191, miR-500, miR-30d, and miR-150) were upregulated ( Figure 1A ; Online Figure IA) . Out of these 8 deregulated miRNAs, only miR-210 was significantly altered throughout multiple testing using Bonferroni post hoc analysis. In plasma from a separate second BiKE patient cohort (Online Table II ) of symptomatic versus asymptomatic CEA subjects (7 versus 7), a 1.5-fold downregulation of miR-210 was confirmed. In peripherally sampled arterial plasma taken at the time of surgical intervention, miR-210 was detected in only 5 out of 14 individuals, and miR-210 was not significantly downregulated in patients versus controls (data not shown).
By qRT-PCR analysis of RNA extracted from transverse plaque sections, miR-210 was the only miRNA out of 8 in locally sampled plasma that was substantially and significantly downregulated in whole plaque compared with healthy arterial tissue ( Figure 1B) . We could not detect any difference in miR-210 expression in lesions originating from symptomatic versus asymptomatic patients (Online Figure IB) . To better localize and define a potential role of miR-210 in plaque vulnerability, we performed ISH for miR-210 in histologically graded ruptured (Atherosclerosis Council of the American Heart Association 15 ; type VI) versus stable (type V) carotid plaques with a cap thickness either below (ruptured) or above (stable) the critical 200 μm as defined by Redgrave et al. 16 Patient characteristics for this cohort are listed in Online Table III. Here, miR-210 had a distinct intima-medial localization in control tissue and stable plaques, which almost completely vanished in ruptured lesions ( Figure 1C ; Online Figure IC and ID) , indicating that the unobserved difference in miR-210 expression in whole plaque tissue is mainly attributable to the heterogeneity of advanced human atherosclerotic lesions ( Figure 1D ). Moreover, miR-210 associated with endothelial cells and SMC, and to some extent T cells, whereas APC was associated with SMCs exclusively in ruptured plaques ( Figure 1C ; Online Figure IC) . Localization of miR-210 in the carotid plaque fibrous cap was confirmed in LCMgenerated tissue from fibrous caps, where miR-210 expression was, in concordance with the results of locally drawn plasma, substantially decreased in symptomatic versus asymptomatic patients ( Figure 1E ). In addition to miR-210, we evaluated the expression of other well-established atherosclerosis-associated miRNAs, such as miR-21, 24 miR-29b, 25 miR-126, 26 and miR-145, 27 as well as all other miRNAs identified in our initial local plasma analysis. Apart from miR-210, only miR-21 was significantly deregulated (down) in stable versus ruptured (Online Figure IE) .
To functionally address the role of miR-210 in plaque instability, we examined expression of all experimentally validated miR-210 target genes (Online Table IV) , 17 which were deregulated in previously published BiKE microarray data sets.
14 Among these, APC emerged as a well-known tumor suppressor gene and miR-210 target. 28, 29 APC has an important inhibitory function in canonical Wnt signaling, which in SMCs contributes to the balance between proliferation and apoptosis. 30, 31 Because these mechanisms are assumed to be critical in fibrous cap stability, we addressed APC expression in LCM-dissected fibrous caps from ruptured versus stable plaques and found APC upregulated ( Figure 1E ), corresponding with the observed miR-210 changes. Of note, similar to miR-210, APC was not altered in whole plaque tissue from symptomatic versus asymptomatic patients (Online Figure IF) . Other miR-210 targets contributing to atherosclerosis via apoptosis (PTPN1), 32 angiogenesis (EFNA3), 28 and metabolism (ICSU) 33 were not deregulated in the BiKE tissue microarray data sets.
14 miR-210 Targets APC mRNA at Its 3′-UTR APC is a predicted miR-210 target but has not yet been strongly confirmed as such. 17 To determine whether miR-210 directly targets APC at its 3′-UTR, HEK293 cells or HCtASMCs transfected either with empty (control) pLS-promoter or pLS-APC 3′UTR were coincubated with scrambled control or premiR-210. Relative luciferase activity was significantly reduced in premiR-210-treated cells, suggesting that miR-210 targets APC through its 3′-UTR ( Figure 1F ; Online Figure IIC and IID). 34 In the search for potential miR-210 binding sites at the APC 3′-UTR, we used the RNA22 program as described previously. 18 We identified 3 putative miR-210 binding sites (BS-1, 
miR-210 Is Repressed in Experimental Carotid Artery Remodeling
Carotid artery balloon injury in rats is a well-established model to study the initial response to vascular injury 20 and triggers remodeling and neointima formation via SMC proliferation and survival as depicted in Figure 2A .
In carotid artery tissue from male Sprague-Dawley rats, we detected a significant decrease in miR-210 expression in injured versus intact (contralateral) rat carotid arteries during the first 2 weeks after injury ( Figure 2B ). ISH for miR-210 confirmed that the tunica media-localized miR-210 was lower in injured versus intact rat carotid arteries (Online Figure IIE) . Concordant with miR-210 downregulation after balloon injury in rats, carotid arterial tissue showed significant miR-210 target mRNA upregulation of Apc during the critical 2-week period after injury, when compared with the contralateral intact carotid artery ( Figure 2B ). 
miR-210 Located in the Fibrous Cap Influences Experimental Atherosclerotic Plaque Stability
In a more advanced atherosclerosis setting, morphological analysis revealed that incomplete carotid artery ligation followed by cast placement in male Apoe −/− mice ( Figure 3A ) results in a variety of pathological changes similar to vulnerable atherosclerotic lesion formation, including an accelerated necrotic core evolution, intraplaque hemorrhage, thinned fibrous caps, endothelial fissures, and eventual atherothrombotic events ( Figure 3B ; Online Figure IIIA) . The plaque-triggering ligation in this model is based on altered shear stress rather than flow cessation, and we did not experience any flow cessation (Online Movie). The overall inducible plaque rupture rate was 58%. In carotid arterial tissue from mice with ruptured versus nonruptured or stable plaques and contralateral control arteries (left side; Online Figure IIIB) , no significant difference in miR-210 expression was detected (Online Figure IIIC) .
ISH of ruptured versus nonruptured carotid arteries confirmed that whole-vessel miR-210 expression was not significantly altered between the groups and control arteries, but as in human lesions, the fibrous caps of ruptured plaques showed less miR-210 expression when compared with nonruptured plaques and control carotid arterial tissue ( Figure 3C ). Staining for α-smooth muscle actin indicated that the fibrous cap of ruptured plaques contained fewer SMCs ( Figure 3C ).
miR-210 Mimics Prevent Carotid Plaque Rupture In Vivo
To investigate the association between fibrous cap miR-210 expression, SMC survival, and clinically meaningful lesion vulnerability, we used the mouse plaque rupture model to investigate whether miR-210 modulation can influence plaque stability and rupture rate. FAM-labeled oligonucleotides delivered intraperitoneally were successfully incorporated into the carotid arteries ( Figure 4A ). miR-210 inhibition using locked nucleic acid-modified anti-miR-210 antisense oligonucleotides did not significantly increase rupture rate when compared with similarly delivered negative control (scrambled oligonucleotides, Figure 4B ). However, miR-210 overexpression using polyethyleneimine delivered (Jet-PEI, Polyplus-Transfection) miR-210 mimics substantially decreased the rupture rate when compared when Jet-PEI-delivered scrambled control and untreated animals ( Figure 4B ).
α-smooth muscle actin (Acta2) mRNA was increased in carotid artery tissue from mice treated with miR-210 mimics when compared with scrambled and anti-miR-210-treated mice ( Figure 4C ), suggesting that miR-210 exerts its plaque stabilizing effect by increasing plaque SMC content.
Administration of anti-miR-210 in mice significantly increased Apc mRNA in carotid artery lesions (Online Figure  IIID) . In mice receiving miR-210 mimics, Apc was not measurably downregulated (Online Figure IIID) , likely because of the fact that the mRNA was not fully degraded by miR-210 binding, but instead rendered inactive via cleaving and thus still detectable with qRT-PCR. Of importance, APC was suppressed on the protein level in carotid artery lesions as shown and quantified by carotid immunohistochemical staining ( Figure 4D ), as well as in liver tissue indicated by Western blotting (Online Figure IIIE) . Inversely, administration of anti-miR-210 increased the amount of APC-positive cells in destabilized atherosclerotic plaques when compared with scrambled control and miR-210 mimics ( Figure 4D ). In addition, miR-210 overexpression significantly blocked the SMC apoptosis rate in murine fibrous caps ( Figure  4D ). ISH for miR-210 in mice treated with miR-210 mimics or anti-miR-210 was consistent with the modulation (Online Figure  IIIF) . Administration of miR-210 mimics or anti-miR-210 did not alter lesion B and T-cell influx (Online Figure IIIF In an atherosclerosis development model using 12-weekold Apoe −/− mice receiving chronic miR-210 modulation, but without any surgical intervention, miR-210 inhibition nor stimulation affected plasma cholesterol (high-density lipoprotein and low-density lipoprotein) and triglyceride levels (Online Figure VA) -or atherosclerosis development per se as assessed by aortic arch en face Sudan IV and aortic root Oil Red O staining (Online Figure VB through VE) . Aortic root plaque T cell, α-smooth muscle actin, and macrophage content also remained unchanged (Online Figure VF) .
miR-210 Prevents SMC Apoptosis Through Targeting of APC In Vitro
In pathological conditions such as atherosclerosis, the vascular endothelial cell layer becomes insufficient in covering the proliferating SMCs. 35 Different types of fluid shear stress can evoke a variety of reactions in these cells, including perpetuating the process of fibrous cap instability. 36 Focusing on human carotid artery SMCs (HCtASMCs), considered essential for stabilization of the fibrous cap, 1 we used an isolated system that subjected them to physiological (laminar) or pathological (oscillatory) fluidic flow In oscillatory versus laminar conditions, APC mRNA was upregulated ( Figure 5B ). Serum starvation of HCtASMCs caused a significant miR-210 downregulation concomitant with APC induction ( Figure 5C ). The tumor suppressor p53 has previously been identified as an upstream regulator of miR-210 under hypoxia. 29 In starved HCtASMCs, inhibition of p53 with its specific antagonist pifithrin-α prevented miR-210 downregulation ( Figure 5D ). Oscillatory and laminar flow did not cause significant changes in HCtASMC miR-210 release into the supernatant (Online Figure  VIB) . Flow did cause a slight upregulation of cellular Wnt signaling, as measured by TCF/LEF transcription in HCtASMCs when compared with static conditions (Online Figure VIC) .
Successful in vitro miR-210 overexpression and inhibition was confirmed by qRT-PCR (Online Figure VID) . miR-210 overexpression significantly decreases APC protein levels in HCtASMCs ( Figure 5E ; Online Figure VIA ) but does not impede mRNA expression (Online Figure VIE) or HCtASMC proliferation in vitro (Online Figure VIF) . However, because APC is a tumor suppressor gene associated with programmed cell death, we used a TUNEL assay to further evaluate whether miR-210 has an antisurvival effect on HCtASMCs. After confirming successful miRNA transfection in vitro (Online Figure VIG) , we modulated miR-210 to assess its cellular effects, showing that transfection with premiR-210 significantly inhibited HCtASMC apoptosis ( Figure 5F and 5G).
To strengthen the rationale that miR-210 reduces SMC apoptosis via inhibition of APC, modulation of miR-210 and APC siRNA knockdown was evaluated. miR-210 overexpression and APC silencing reduced APC protein expression as indicated with immunofluorescence staining (Online Figure VIIA) and consequentially suppressed cell apoptosis ( Figure 6A and 6B) after stimulation with etoposide.
In canonical Wnt signaling, APC is part of a destruction complex preventing β-catenin from entering the nucleus, a translocation necessary to coactivate proliferative transcription factors, including the TCF/LEF family. 37 APC siRNA knockdown and miR-210 mimics in HCtASMCs evoked nuclear localization of β-catenin ( Figure 6C and 6D) . In HEK293 cells, anti-miR-210 and miR-210 mimics had opposing effects on TCF/LEF-dependent signaling, with overexpression of miR-210 resulting in a substantial increase of signaling activity ( Figure 6E ). However, less pronounced than in HEK293 cells, miR-210 mimics stimulated TCF/LEF signaling in HCtASMCs, an effect abolished by APC overexpression (Online Figure VIIC and VIID) . Taken together, our in vitro findings strengthen the hypothesis that miR-210 is a crucial regulator of advanced atherosclerotic lesion fate by stimulating canonical Wnt signaling via inhibition of APC in SMCs as schematically illustrated in Figure 7 .
Discussion
Today's clinical debate in carotid atherosclerotic disease as a cause of stroke is focused around the identification of the vulnerable patient and the prevention of plaque rupture. Novel imaging modalities provide increasing levels of sensitivity and specificity 38, 39 in determining plaque vulnerability. The implementation of this knowledge in clinical practice is however obstructed by the relatively high operational risk of presentday treatment options (CEA and carotid artery stenting) for asymptomatic individuals with carotid stenosis. A less invasive plaque sealing method, based on local (eg, ultrasound mediated 40 ) delivery of fibrous cap stabilizing agents acting on a cellular level, might provide a more refined treatment choice.
The rise of miRNAs as endogenous disease biomarkers and modulators has caused an enormous interest in experimentally measuring and therapeutically manipulating their expression. The particular sensitivity of the human cardiovascular system to subtle gene expression alterations might be an ideal target for miRNAs as they fine tune biological processes. 41 By exploiting locally sampled plasma and fibrous cap tissue, we identified miR-210 as the main miRNA being synthetized and released into the local cellular milieu by cells in the fibrous cap of carotid plaques, with unstable plaques releasing only limited amounts of miR-210.
Although we did not observe severe off-target effects of miR-210 mimics, such as cardiac remodeling or kidney fibrosis, reports linking miR-210 with various forms of cancer suggest that miR-210 treatment needs to be applied with caution. Induced under hypoxic conditions 28 and targeting tumor suppressor genes, 42 miR-210 overexpression is classically associated with cancer. Elevated miR-210 expression levels have been linked to a higher prevalence and a poor prognosis in breast, head, and neck, as well as pancreatic cancer, partly because of a diminished response to therapy. 43 If a plaque stabilizing miR-210 therapy is to be considered, potentially tumorigenic offtarget effects should be taken into account and prevented-or at least minimized using a local delivery strategy. Local delivery of vascular therapeutic miRNA modulators via coated stents has recently been shown to be safe and highly effective. 44 Direct delivery of miR-210 attenuates cardiac injury in mice and has been suggested as a therapeutic agent in ischemic heart disease. 45 Results from our study indicate that not only hypoxia, but also other stimuli, including pathological shear stress and altered blood flow conditions, as well as conditions inducing apoptosis and dedifferentiation, can lead to miR-210 repression in the vasculature, resulting in a downstream induction of proapoptotic mechanisms mainly in SMCs. Apoptosis of these cells in the fibrous cap of an atherosclerotic plaque is an important step toward the vulnerable phenotype. 1, 46 Furthermore, atherogenic wall shear stress, also referred to as disturbed or turbulent, is known to strongly trigger (maladaptive) changes in vascular cell subtypes, 47 which in our study was attributed to loss of miR-210. Among validated miR-210 targets, APC is an important rate-limiting component in canonical Wnt signaling, making it one of the most infamous tumor suppressor genes; loss-offunction mutations are well known to cause colon cancer. 37 Wnt signaling in SMCs regulates a variety of atherosclerotic processes, such as proliferation, migration, differentiation, and apoptosis, all crucially involved in plaque stability. 30 Stimulation of the Wnt-β-catenin axis leads to an increased SMC survival, whereas a reduction in β-catenin downstream signaling increases SMC apoptosis rates. 31 We confirmed this by showing that APC, β-catenin, and TCF/LEF modulation by miR-210 directly regulates SMC apoptosis (Figure 7) .
After acute balloon-induced carotid artery injury in rats, miR-210 downregulation and concordant Apc upregulation correlated with arterial remodeling. In induced mouse carotid plaque rupture, closely resembling the human disease with respect to plaque miR-210 expression ( Figure 3C ), APC protein levels correlated with advanced plaque instability ( Figure  4D ). By modulating miR-210 expression in vivo, we were able to re-establish miR-210 in carotid arteries, evoking a protective response in lesion site SMCs through inhibition of Apc. Salvaged from apoptosis, these cells stabilized the fibrous cap, resulting in substantially less plaque ruptures. Interestingly, miR-210 modulation solely enhanced fibrous cap stability by triggering SMC survival, while not affecting atherosclerosis development and progression in general.
Because of the immense complexity of miRNA influence on different signaling pathways, caution is required when presenting miRNA modulation as the ultimate solution to vascular pathologies. Off-target effects, pharmacokinetics and dynamics, and metabolic consequences need to be addressed. In this study, we have combined molecular and biophysical basics with in vivo applied miRNA modulation, taking human subjects as a starting point. This approach is essential in making vascular miRNA modulation a near-future therapeutic option, instead of a remote possibility. Local delivery of miR-210 mimics, using drug-eluting balloons/stents or ultrasound-triggered nanodelivery technology, would certainly enhance the translational feasibility of establishing miR-210 induction into clinically relevant plaque sealing approaches in patients with unstable carotid artery disease and enhanced risk of ischemic stroke.
